验证数据展示
产品信息
12892-1-PBS targets TDP-43 (C-terminal) in WB, IHC, IF/ICC, IF-Fro, FC (Intra), IP, ELISA applications and shows reactivity with human, mouse, rat samples.
| 经测试应用 | WB, IHC, IF/ICC, IF-Fro, FC (Intra), IP, ELISA Application Description |
| 经测试反应性 | human, mouse, rat |
| 免疫原 |
fusion protein 种属同源性预测 |
| 宿主/亚型 | Rabbit / IgG |
| 抗体类别 | Polyclonal |
| 产品类型 | Antibody |
| 全称 | TAR DNA binding protein |
| 别名 | TARDBP, TDP 43, TDP43, TDP-43, ALS10 |
| 计算分子量 | 43 kDa |
| 观测分子量 | 43-45 kDa, 35 kDa |
| GenBank蛋白编号 | BC001487 |
| 基因名称 | TDP-43 |
| Gene ID (NCBI) | 23435 |
| RRID | AB_2200505 |
| 偶联类型 | Unconjugated |
| 形式 | Liquid |
| 纯化方式 | Antigen affinity purification |
| UNIPROT ID | Q13148 |
| 储存缓冲液 | PBS only, pH 7.3. |
| 储存条件 | Store at -80°C. The product is shipped with ice packs. Upon receipt, store it immediately at -80°C |
背景介绍
Transactivation response (TAR), DNA-binding protein of 43 kDa (also known as TARDBP or TDP-43), was first isolated as a transcriptional inactivator binding to the TAR DNA element of the HIV-1 virus. Neumann et al. (2006) found that a hyperphosphorylated, ubiquitinated, and cleaved form of TARDBP, known as pathologic TDP-43, is the major component of the tau-negative and ubiquitin-positive inclusions that characterize amyotrophic lateral sclerosis (ALS) and the most common pathological subtype of frontotemporal lobar degeneration (FTLD-U). 12892-1-AP is a rabbit polyclonal antibody raised against the C-terminal amino acids of human TDP-43. This antibody recognizes the cleavage product of 20-30 kDa in addition to the native and phosphorylated forms of TDP-43. Immunohistochemical analyses of TDP-43 using this antibody detect both normal diffuse nuclear staining and insoluble inclusions in pathologic tissues. Various forms of TDP-43 exist, including 18-35 kDa of cleaved C-terminal fragments, 45-50 kDa phosphoprotein, 55 kDa glycosylated form, 75 kDa hyperphosphorylated form, and 90-300 kDa cross-linked form. (17023659,19823856,21666678,22193176)
Recently TDP-43 has been reported to be overexpressed in triple negative breast cancer (TNBC) and it may be a potential target for TNBC diagnosis and drug design. (29581274)















